Bristol-Myers Squibb Co. (BMY)

49.05
0.67 1.30
NYSE : Health Technology
Prev Close 49.72
Open 49.60
Day Low/High 49.10 / 50.26
52 Wk Low/High 44.30 / 70.05
Volume 14.94M
Avg Volume 11.69M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 78.31B
EPS 0.60
P/E Ratio 53.90
Div & Yield 1.64 (3.33%)

Latest News

Jim Cramer: There's a Ton More Deals in the Pipe

Jim Cramer: There's a Ton More Deals in the Pipe

Deals that simply were unworkable four months ago because of price are now being done with alacrity.

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman is top of the heap for takeovers.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Try This Allergan Two-Week Setup

Try This Allergan Two-Week Setup

The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.

European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) For First-Line Treatment Of Patients With Intermediate- And Poor-Risk Advanced Renal Cell Carcinoma

European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) For First-Line Treatment Of Patients With Intermediate- And Poor-Risk Advanced Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg ("low-dose") for the first-line treatment of patients with intermediate- and...

The Gold Rush of 2019

The Gold Rush of 2019

Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.

Pfizer and the Urge to Merge

Pfizer and the Urge to Merge

My stated reason for being in Pfizer all along has been price stability and income.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

Real Money Post Industrial Average Outperformed the Market in 2018

Real Money Post Industrial Average Outperformed the Market in 2018

The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

Could there be more M&A this year than Wall Street had thought? Also, GE's quest for more liquidity took another baby step Monday.

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

Tesla, the big pharma mergers and General Electric are some of the top stories on TheStreet.

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft is to be bought for about $2 billion by DXC Technology.

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

The company expects revenue to jump 12% year over year.

What the Action Alerts Plus Portfolio Is Looking at This Week

What the Action Alerts Plus Portfolio Is Looking at This Week

Are you ready for the week? Action Alerts Plus's Zev Fima breaks down what the portfolio is watching.

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly & Co. says Monday it will pay $8 billion in cash for cancer drug specialists Loxo Oncology in the second major pharmaceutical sector deal of the year.

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.

Jim Cramer: These Pharma Deals Are Game Changers

Jim Cramer: These Pharma Deals Are Game Changers

Pharma companies that have cash are looking at what has happened to this stock market and buying.

Bristol-Myers Squibb To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Bristol-Myers Squibb To Participate In The 37th Annual J.P. Morgan Healthcare Conference

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Giovanni Caforio, M.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Keep an Eye on Earnings: Cramer's 'Mad Money' Recap (Thursday 1/3/19)

Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.

3 Things to Know at Market Close: Apple, Bristol-Myers and the Jobs Report

3 Things to Know at Market Close: Apple, Bristol-Myers and the Jobs Report

Bristol-Myers, Apple and the economy are some of the top stories on TheStreet.

Dow Drops More Than 600 Points on Apple Warning, China Fears

Dow Drops More Than 600 Points on Apple Warning, China Fears

All three major indices dropped more than 2% Thursday.

Bristol-Myers Squibb Tabs Cancer Drug Specialist Celgene in $74 Billion Takeover

Bristol-Myers Squibb Tabs Cancer Drug Specialist Celgene in $74 Billion Takeover

Bristol-Myers Squibb agrees to buy Celgene in a deal that values the cancer drug specialist at $74 billion.

TheStreet Quant Rating: C+ (Hold)